CALGENT focuses on developing new molecular entities (NME) drugs based on our innovative clinical treatment strategies. Besides, we are also committed to accelerate developing new indications and new formulation drugs for unmet medical needs through innovative solutions. CALGENT makes a strong global patent portfolio to protect our core technical know-how, breakthrough drugs, scientific and technological achievements.